Simone Filosto

6PUBLICATIONS
71CO-AUTHORS
ChemotherapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 21, 2026
Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel.

|Apr 06, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Naval Daver, James S Blachly, Armin Ghobadi

|Jul 07, 2025
Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.

Assia Hijazi, Frederick L Locke, Nathalie Scholler

|Nov 20, 2023
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).

Simone Filosto, Saran Vardhanabhuti, Miguel A Canales

|Aug 01, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.

Michael D Jain, David B Miklos, Caron A Jacobson

|Mar 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.

Jason R Westin, Frederick L Locke, Michael Dickinson

Pageof 1

Frequent Collaborators

3 joint publications

Christina To

2 joint publications

Jason R Westin

2 joint publications

Frederick L Locke

2 joint publications

Armin Ghobadi